Bibliographies thématiques / Section 29.21 CCA

Littérature scientifique sur le sujet « Section 29.21 CCA »

Auteur : Grafiati
Publié le 11 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Section 29.21 CCA ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Section 29.21 CCA"

1

Leffers, H. C. B., M. L. Hermansen, B. Sandholt, A. Fuchs, H. Sillesen, L. Køber, K. F. Kofoed, M. Faurschou et S. Jacobsen. « Plasma levels of β2-microglobulin are associated with atherosclerosis in patients with systemic lupus erythematosus : a cross-sectional cohort study ». Lupus 27, no 9 (28 juin 2018) : 1517–23. http://dx.doi.org/10.1177/0961203318784661.

Texte intégral
Résumé :
Objective The objective of this paper is to examine the association between plasma levels of β2-microglobulin (β2MG), a protein previously associated with atherosclerosis, and the presence of carotid plaque (CP) or coronary artery calcium (CAC) in a cross-sectional cohort study of patients with systemic lupus erythematosus (SLE). Methods Patients with SLE were enrolled between June 2013 and May 2014. The presence of CP and CAC was assessed with ultrasonography and computed tomography scan, respectively. The presence of CP or CAC in the SLE patients was analyzed with respect to plasma levels of β2MG and renal function expressed as the estimated glomerular filtration rate (eGFR). Results The study cohort consisted of 147 patients, 89% women and 95% Caucasians. The median age was 46 (range: 21–75) years with a median disease duration of 14 years. CP and CAC was observed in 29 (20%) and 57 (39%) of patients, respectively. CP or CAC was seen in 62 (42%) patients and was associated with the highest quartile of plasma β2MG in patients with eGFR ≥ 90 ml/min/1.73 m2; OR = 18 (95% CI: 1.7–181). β2MG adjusted for eGFR was also associated with presence of CP or CAC in the total cohort. The exclusion of 25 patients with a prior history of cardiovascular disease did not change the observed associations. Conclusion In this study, we found significant associations between imaging markers of atherosclerosis and high plasma levels of plasma β2MG. These data suggest that β2MG is a candidate for further study as a biomarker for atherosclerosis in SLE.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Javle, Milind M., Karthikeyan Murugesan, Rachna T. Shroff, Mitesh J. Borad, Reham Abdel-Wahab, Alexa Betzig Schrock, Jon Chung et al. « Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). » Journal of Clinical Oncology 37, no 15_suppl (20 mai 2019) : 4087. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4087.

Texte intégral
Résumé :
4087 Background: The management of CCA has evolved as targeted and immune checkpoint inhibitor (ICPI) therapies have emerged. We used comprehensive genomic profiling (CGP) to characterize the genomic alterations (GA) that have potential to personalize therapy for CCA. Methods: 3634 CCA underwent hybrid capture based CGP on 0.8-1.1 Mb of the coding genome to identify GAs in exons and select introns in up to 404 genes, TMB, microsatellite status (MSI) and % monoallelic genome (gLOH). PD-L1 expression was determined by IHC (Dako 22C3). Results: 52% of CCA were female with a median age of 62 years (range 16 - > 89). The most common biopsy sites were liver (74%), lymph node (4%), bile duct (3.3%), and lung (2%). MSI-high was rare (1%), 118 and 47 cases had TMB > 10 and > 20 mut/mb respectively. Of the latter, 51% (24/47) were MSI-H. PD-L1 amplification (AMP) was present in 0.27%. Of 490 CCA tested, 43 (9%) were positive for PD-L1 expression. 11% of cases had gLOH > 16%, only 2 cases had both TMB > 20 and gLOH > 16%. GA were most common in TP53 (31%), CDKN2A (29%), KRAS (20%) and ARID1A (17%). Potentially targetable GAs included FGFR2 (11%, 85% fusions), BRAF (5%, 50% V600E), ERBB2 (5%, 72% AMP), MET (2%, 90% AMP), EGFR (0.52%) and rarer ( < 0.5%) FGFR3, RET, FGFR1, ALK, and ROS1 fusions. The FGFR2 fusions had 128 unique 3’ partner genes including BICC1 (26%), CCDC6 (3.2%), AHCYL1 (2.6%) and KIAA1217 (2.6%). FGFR2 fusions occurred in a mutually exclusive fashion from high gLOH (p < 0.002), but not high TMB. GA in IDH1 (15%) were mutually exclusive of FGFR2 fusions (p < 1e-13), but co-occurred with PBRM1 GA (23%, p < 1e-21), ARID1A (26% p < 1e-10). IDH1 GA had gLOH similar to the overall CCA population but were enriched for low TMB (p < 1e-3). Conclusions: Nearly 20% of CCA cases harbor targetable kinase GA, half of which were FGFR2 fusions. Independently, an additional 10% (gLOH) and 1% (high TMB, MSI and/or PD-L1 AMP) may benefit from PARP inhibitors and ICPI respectively. Independently, co-mutation of IDH1 and PBRM1/ARID1A defines a class of CCA that warrants further investigation for sensitivity to PARP inhibitors and may serve as a paradigm for other tumors (ie. gliomas) with a similar co-occurrence landscape.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Thomas, Jacob Stephen, Heinz-Josef Lenz, Syma Iqbal, Denice D. Tsao-Wei, Afsaneh Barzi, Vinay Duddalwar, Sarah Cole et al. « A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA). » Journal of Clinical Oncology 36, no 4_suppl (1 février 2018) : 285. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.285.

Texte intégral
Résumé :
285 Background: EphrinB4, a receptor kinase, is associated with stage and survival in epithelial cancers. sEphB4 is a fusion protein of soluble EphB4 and albumin. sEphB4 binds to EphrinB2, a protein expressed in tumor cells and vessels, and blocks bidirectional signaling. sEphB4 downregulates the PI3K/AKT/mTOR pathway, inhibits angiogenesis, and promotes recruitment of cytotoxic T cells and NK cells. MTD was not reached during dose escalation. The RP2D was 10 mg/Kg weekly. Here we report the results of the expansion cohorts in HCC and CCA. Methods: The study evaluated the safety, PK, PD and efficacy of sEphB4 in pts with advanced solid tumors in a 3+3 design with expansion at the RP2D in 7 solid tumors including HCC and CCA. Pts received sEphB4 10 mg/kg IV weekly in 28-day cycles. Eligibility included ECOG 0-1, Child-Pugh score ≤ 7, platelets > 50,000, AST/ALT ≤ 3xULN, serum bilirubin ≤ 1.5mg/dL and no uncontrolled hypertension. Results: 29 pts were treated: 17 HCC and 12 biliary cancers (8 CCA and 4 gallbladder). Median age was 63(25-77). ECOG PS was 1 in 76%. Median prior regimens were 1 (0-6) for HCC and 2 (1-3) for biliary cancers. 2 HCC pts had prior liver transplantation, 9 had prior anti PD-1 therapy and 2 had Child-Pugh score of B7. Median number of cycles was 4 (1-21) in HCC and 2 (1-17) in CCA. No grade 4 treatment-related adverse events (TRAE). Grade 3 TRAE were hypertension (41%) and fatigue, headache, neutropenia all in 1 pt each. Disease progression was the most common reason for treatment discontinuation. Median PFS in months was 5.0 (3.0-7.5) in HCC and 3.0 (1.6-9.2) in CCA. Median OS in months was 27.1 (4.4-27.1) in HCC and 12.0 (3.0-28.2) in CCA. Disease control rate was 70% in HCC and 42% in CCA including 1 PR in HCC. In HCC pts, 5/5 with 3+ EphrinB2 expression in tumor had PR or SD ≥ 6 months. Only 1/4 pts with ≤2+ expression had SD ≥ 4 months. 3/3 pts with HCC showed an increase in T cell infiltration, and decrease in pS6 (PI3K pathway activity) on post-treatment biopsy. Conclusions: sEphB4 has a manageable safety profile with preliminary evidence of anti-tumor activity in pretreated pts with HCC and biliary cancers. Several trials combining sEphB4-HSA with cytotoxic chemotherapy or immunotherapy are ongoing. Clinical trial information: NCT01642342.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Geltman, D. V. « Nomenclature Section of XIX International Botanical Congress (July 17–21, Shenzhen, People’s Republic of China) : activity and principal decisions ». Novitates Systematicae Plantarum Vascularium 48 (2017) : 5–12. http://dx.doi.org/10.31111/novitates/2017.48.5.

Texte intégral
Résumé :
Nomenclature Section of XIX International Botanical Congress (Shenzhen, People’s Republic of China) worked during July 17–21. 155 delegates from 29 countries participated in this section; they have also 427 institutional votes. Of 397 proposals to amend International code of nomenclature for algae, fungi and plants 113 ones (28.5%) were accepted as such or with amendments. The paper contains brief characteristics of the activity of the Nomenclature Section and the review of its principal decisions which in comparison with those adopted by previous, XVIII International Botanical Congress (Melbourne) look conservative enough.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Parikh, Kinjal, Davecia Ragoonath Cameron, Tristin Abair, Patrick Kugel et Arndt Vogel. « Targeted therapies in cholangiocarcinoma : Assessment of US oncologist practice patterns. » Journal of Clinical Oncology 39, no 3_suppl (20 janvier 2021) : 347. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.347.

Texte intégral
Résumé :
347 Background: Chemotherapy is a mainstay treatment modality for patients with advanced cholangiocarcinoma (CCA). Recent developments and new approvals have led to changing paradigms, incorporating the use of targeted therapies for patients with progressive disease. Given the need for a greater understanding of the molecular alterations, varying targets, and available and emerging therapies, education is needed to assess knowledge regarding these recent advances in unresectable CCA. The goal of this activity was to increase the knowledge of self-assess the learning needs of oncologists in treating patients with unresectable CCA. Methods: The education included 25 multiple choice questions in a continuing medical education (CME)-certified clinical practice assessment to assess practice gaps. The questions were designed to measure knowledge, competence, confidence, and attitudes of oncologists regarding clinical evidence, role of molecular testing, and place in the treatment paradigm for targeted therapies in unresectable CCA. The self-assessment was made available online to physicians as a learning tool to gain foundational knowledge, as well as receive feedback about their performance as compared to other test-takers, to improve self-awareness of their own personal educational gaps. The activity launched 6/24/20, and data are reported through 8/31/20. Results: A total of 1,009 learners, including 758 physicians, participated in the activity. Of the 104 oncologists that participated, a majority practiced in the community setting, saw patients with a range of cancers, and were not confident about using targeted therapies or recognizing targets for biomarker testing. Oncologists demonstrated the following gaps related to: NGS sequencing and biomarkers: 21% do not use; 32% use upon progressive disease; 35% did not realize that not all panels detect FGFR2 fusions; 20% do not test for biomarkers; 29% and 56% test for IDH or FGFR, respectively; 60% recognize the incidence of IDH1 mutations; Clinical trial (FIGHT202 and ClarIDHy): 45% were able to identify biomarker eligibility for pemigatinib; 9% were able to identify pemigatinib OS outcomes; 30% were able to recognize most common grade 3 AE of pemigatinib; 51% recognized the PFS endpoint with ivosidenib; 34% were able to identify eligibility for ivosidenib; 55% recognized most common AEs of ivosidenib. Conclusions: This CME-certified clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and use of targeted therapies and emerging data in patients with unresectable CCA. As new data emerges and the number of targets and targeted therapies expand, continued education remains important to continue to optimize patient care.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Deutsch, H., K. Becker, J. Pittner, V. Bonacic-Koutecky, S. Matt et T. D. Märk. « Semiclassical calculations of the cross section for electron-impact ionization of ». Journal of Physics B : Atomic, Molecular and Optical Physics 29, no 21 (14 novembre 1996) : 5175–81. http://dx.doi.org/10.1088/0953-4075/29/21/027.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Feng, Yin-Hsun, Wu-Chou Su, Do-Youn Oh, Lin Shen, Kyu-Pyo Kim, Xiufeng Liu, Huimin Liao et al. « Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations. » Journal of Clinical Oncology 40, no 4_suppl (1 février 2022) : 430. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.430.

Texte intégral
Résumé :
430 Background: Pts with CCA progressing after first-line therapy have limited treatment options. We report an updated analysis of the ongoing LUC2001 open-label, multicenter, phase 2a study (NCT02699606) investigating the efficacy and safety of erdafitinib in Asian pts with advanced CCA and FGFR alterations who progressed after ≥1 prior systemic treatment. Methods: Eligible adults (aged ≥18 years) received erdafitinib 8 mg once daily (QD) with pharmacodynamically guided up-titration to 9 mg QD. The primary endpoint was objective response rate (ORR; RECIST 1.1); secondary endpoints included best overall response (BOR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Survival estimates were determined by the Kaplan–Meier method. Results: Of 232 patients with CCA who underwent molecular screening, 39 (16.8%) had FGFR alterations (21 [9.1%] fusions and 19 [8.2%] mutations). Overall, 22 (9.5%) eligible pts (median age, 52 [range, 29–69] years) were enrolled and received treatment. Median follow-up was 22.4 (range, 2.3–47.0) months; median treatment duration was 6.2 (range, 1.5–35.6) months. All 22 pts received ≥1 line of prior systemic therapy and 12 (55.0%) pts had ≥2 prior lines of therapy. The ORR was 40.9% (95% CI, 20.7%–63.6%) and median time to response was 1.8 (range, 1.5–5.6) months. Median DOR was 7.3 (95% CI, 3.7–17.5) months, median PFS was 5.6 (95% CI, 3.6–12.7) months, and median OS was 40.2 (95% CI: 9.9–not estimable) months (Table). Responses were observed in 8/14 pts with FGFR fusions and 1/8 pts with FGFR mutations and in pts who received 1 or ≥2 prior lines of therapy. All 22 pts had ≥1 treatment-emergent adverse event (TEAE), the most common being dry mouth (15/22 [68.2%]) and stomatitis (14/22 [63.6%]). Grade ≥3 TEAEs occurred in 15/22 (68.2%) pts (11/22 [50.0%] were treatment related), of which the most common were stomatitis (3/22 [13.6%]) and alanine aminotransferase (ALT) increased (3/22 [13.6%]); 11/22 (50.0%) pts had ≥1 serious TEAE (1/22 [4.5%] pts had a serious treatment-related TEAE). A TEAE leading to death occurred in 1 patient (sepsis; not treatment-related). Conclusions: Asian pts with advanced CCA and FGFR alterations treated with erdafitinib had durable efficacy and a manageable safety profile, supporting the earlier findings of erdafitinib benefit in this population. Clinical trial information: NCT02699606. [Table: see text]
Styles APA, Harvard, Vancouver, ISO, etc.
8

Primrose, W. J., G. D. L. Smyth, A. G. Kerr et D. S. Gordon. « Vestibular nerve section and saccus decompression : An evaluation of long-term results ». Journal of Laryngology & ; Otology 100, no 7 (juillet 1986) : 775–84. http://dx.doi.org/10.1017/s0022215100100076.

Texte intégral
Résumé :
AbstractThe 1972 AAOO committee (Alford, 1972) guidelines brought some uniformity into the evaluation of therapy for Meniere's Disease. We have adhered to its recommendations in this long-term follow-up report of 21 saccus decompressions and 29 vestibular nerve sections performed on 46 patients between 1968 and 1977. Comparisons between these and other groups have been possible with regard to: 1. control of vertigo; 2. hearing; 3. tinnitus; and 4. development of hydrops in the contralateral ear. All the vestibular nerve section group have enjoyed sustained relief from vertigo. Class D results (recurrent vertigo) account for 14 per cent of the saccus decompression group at one year and 29 per cent at eight to 10-year follow-up. Hearing levels in both groups deteriorated in parallel as time progressed but tinnitus became less noticeable. Nineteen per cent of the long-term review patients showed evidence of developing cochlear hydrops in the contralateral ear. Conservative surgical procedures should be employed whilst any useful hearing exists, though the emphasis remains on controlling vertigo. Saccus decompression, despite its controversial therapeutic basis, will remain the first-line surgical procedure for many otologists. However, in the fit young Meniere's cripple or saccus decompression failure with serviceable hearing, vestibular nerve section remains the treatment of choice.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Smith, Allan L. « Comparison of the ultraviolet absorption cross section of buckminsterfullerene in the gas phase and in hexane solution ». Journal of Physics B : Atomic, Molecular and Optical Physics 29, no 21 (14 novembre 1996) : 4975–80. http://dx.doi.org/10.1088/0953-4075/29/21/011.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Mikaelian, I., et V. Wong. « Follicular Stem Cell Carcinoma : Histologic, Immunohistochemical, Ultrastructural, and Clinical Characterization in 30 Dogs ». Veterinary Pathology 40, no 4 (juillet 2003) : 433–44. http://dx.doi.org/10.1354/vp.40-4-433.

Texte intégral
Résumé :
Diagnostic records of 30 primary and one metastatic follicular stem cell carcinomas in 30 dogs were reviewed. Neoplastic cells had a clear cytoplasm and formed lobules and nests surrounded by a basement membrane. Trichoepitheliomatous and apocrine differentiations were noted in 22 of 30 (73%) and 21 of 30 (70%) primary tumors, respectively. Glycogen was present in 20 of 20 (100%) tumors tested, suggesting tricholemmal differentiation. Antibodies against AE1/AE3 cytokeratin, vimentin, and melanA/MART1 stained 29 of 30 (97%), 29 of 30 (97%), and 12 of 27 (44%) primary tumors, respectively. Small amounts of melanin were identified in 14 primary tumors, either on the hematoxylin and eosin-stained section ( n = 6), or on the Fontana-stained section ( n = 8 of 14). Ultrastructural features of neoplastic cells included cell junction complexes, swollen mitochondria, neuroendocrine-like granules, and intracytoplasmic non-membrane-bound accumulation of proteinaceous material. Features of this neoplasm are consistent with a follicular stem cell origin. Follow-up information was available for eight dogs. Metastases developed in the draining lymph node at the time of excision of the primary tumor ( n = 1) or subsequently ( n = 3).
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Livres sur le sujet "Section 29.21 CCA"

1

Great Britain. Department of Health and Social Services, Northern Ireland. et Great Britain, dir. Statistics of scientific procedures on living animals : Northern Ireland : prepared pursuant to section 21(7) of the Animals (Scientific Procedures) Act 1986 as adapted by section 29 of that Act. Belfast : The Stationery Office, 1999.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Northern Ireland. Department of Health, Social Services and Public Safety., dir. Statistics of scientific procedures on living animals : Northern Ireland : prepared pursuant to section 21(7) of the Animals (Scientific Procedures) Act 1986 as adapted by section 29 of that Act. Belfast : Stationery Office, 2003.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Northern Ireland. Department of Health, Social Services and Public Safety., dir. Statistics of scientific procedures on living animals : Northern Ireland : prepared pursuant to section 21(7) of the Animals (Scientific Procedures) Act 1986 as adapted by section 29 of that Act. Belfast : Stationery Office, 2002.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Section 29.21 CCA"

1

« Lecture 21 Chapter 7, Section E : Primary and Secondary Processes ». Dans Kohut's Freudian Vision, 90–92. Routledge, 2016. http://dx.doi.org/10.4324/9781315784175-29.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Medury, Renuka. « Trade mark dilution before and after Section 29(4) of the Indian Trade Marks Act ». Dans Annotated Leading Trademark Cases in Major Asian Jurisdictions, 240–51. Routledge, 2019. http://dx.doi.org/10.4324/9780429316395-21.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Section 29.21 CCA"

1

Fritz, Dominik, Y. Danon, Adam Ney, Peter Brain, Sukhjinder Singh, Katelyn Cook, Benjamin Wang et al. « Thermal Cross Section Measurements At The RPI LINAC [Slides] ». Dans 15.International Conference on Nuclear Data for Science and Technology (ND2022), Held Virtually, Sacramento, CA (United States), 21-29 Jul 2022. US DOE, 2022. http://dx.doi.org/10.2172/1900399.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Chapman, Chris, Marco Pigni, Klaus Guber et Goran Arbanas. « <sup>140,142</sup>Ce Neutron Cross Section Resolved Resonance Region Evaluation [Slides] ». Dans 15.International Conference on Nuclear Data for Science and Technology (ND2022), Held Virtually, Sacramento, CA (United States), 21-29 Jul 2022. US DOE, 2022. http://dx.doi.org/10.2172/1900249.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Brown, Jesse, Klaus Guber, Carlos Paradela, Peter Schillebeeckx et Stefan Kopecky. « Zr Nuclear Data Campaign : Measurement of <sup>90</sup>Zr(n,<em>γ</em>) cross section [Slides] ». Dans 15.International Conference on Nuclear Data for Science and Technology (ND2022), Held Virtually, Sacramento, CA (United States), 21-29 Jul 2022. US DOE, 2022. http://dx.doi.org/10.2172/1901527.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

McDonnell, Jordan, et Marco Pigni. « Updates and Validation for the n+<sup>63,65</sup>Cu Cross Sections [Slides] ». Dans 15.International Conference on Nuclear Data for Science and Technology (ND2022), Held Virtually, Sacramento, CA (United States), 21-29 Jul 2022. US DOE, 2022. http://dx.doi.org/10.2172/1901557.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Section 29.21 CCA » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie